• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $TSHA

    Taysha Gene Therapies Inc.

    Subscribe to $TSHA
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: tayshagtx.com

    Peers

    $ABEO
    $PASG
    $SIOX

    Recent Analyst Ratings for Taysha Gene Therapies Inc.

    DatePrice TargetRatingAnalyst
    6/27/2024$5.00Outperform
    BMO Capital Markets
    4/9/2024$9.00Overweight
    Piper Sandler
    2/1/2023$14.00 → $1.50Buy → Hold
    Jefferies
    1/27/2023$23.00 → $3.00Overweight → Equal-Weight
    Morgan Stanley
    11/9/2022$16.00 → $3.00Buy → Neutral
    Goldman
    3/9/2022$26.00Outperform
    Robert W. Baird
    3/9/2022$26.00Outperform
    Baird
    3/1/2022$25.00Overweight
    Wells Fargo
    2/18/2022$25.00Outperform
    SMBC Nikko
    12/16/2021$28.00Buy
    Guggenheim
    See more ratings

    Taysha Gene Therapies Inc. SEC Filings

    See more
    • SEC Form 8-K filed by Taysha Gene Therapies Inc.

      8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)

      5/29/25 4:38:45 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Taysha Gene Therapies Inc.

      424B5 - Taysha Gene Therapies, Inc. (0001806310) (Filer)

      5/29/25 4:32:50 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: Taysha Gene Therapies Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K/A - Taysha Gene Therapies, Inc. (0001806310) (Filer)

      5/29/25 6:02:26 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Taysha Gene Therapies Inc.

      424B5 - Taysha Gene Therapies, Inc. (0001806310) (Filer)

      5/28/25 5:02:21 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)

      5/28/25 4:13:36 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Taysha Gene Therapies Inc.

      10-Q - Taysha Gene Therapies, Inc. (0001806310) (Filer)

      5/15/25 8:40:07 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)

      5/15/25 8:09:41 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Taysha Gene Therapies Inc.

      SCHEDULE 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

      5/15/25 8:00:13 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFR14A filed by Taysha Gene Therapies Inc.

      DEFR14A - Taysha Gene Therapies, Inc. (0001806310) (Filer)

      5/9/25 4:06:04 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Taysha Gene Therapies Inc.

      DEFA14A - Taysha Gene Therapies, Inc. (0001806310) (Filer)

      4/21/25 4:04:10 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Taysha Gene Therapies Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

      DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 46,868,687 shares of its common stock at a price to the public of $2.75 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 25,858,586 shares of its common stock at an offering price of $2.749 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the sec

      5/28/25 10:40:21 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

      DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities will be offered by Taysha. Taysha also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offere

      5/28/25 4:02:00 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

      Natural history data analysis established patients ≥ six years of age are in developmental plateau, with a ~0% likelihood of gaining/regaining developmental milestones across the core functional domains of Rett syndrome Written alignment from FDA supports single-arm, open label pivotal trial with primary endpoint of developmental milestone gain/regain in the developmental plateau population (≥ 6 years, intend N=15) with each patient serving as their own control 100% of patients in REVEAL Part A (N=10, 6-21 years) gained/regained ≥ one developmental milestone post-TSHA-102 with concordant improvements across multiple outcome measures; high dose consistently outperformed low dose, with dose-

      5/28/25 4:01:00 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Obtained written alignment from the FDA on key elements of TSHA-102 pivotal Part B trial design and next steps on enabling study initiation The FDA advised the Company to submit pivotal Part B trial protocol and associated statistical analysis plan as an amendment to the IND application, eliminating the need for formal end-of-phase meeting and potentially expediting study initiation and registration; IND amendment submission expected in Q2 2025 High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in the pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4) across both REVEAL trials as of April 10, 2025,

      5/15/25 8:00:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

      DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2025, and host a corporate update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM Eastern Time. Conference Call DetailsThursday, May 15, at 8:30 AM Eastern Time / 7:30 AM Central TimeToll Free: 877-407-0792International: 201-689-8263Conference ID: 13753490Webcast: https://ir.tayshagtx.com/news-events/events-presentations

      5/8/25 4:05:00 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      DALLAS, May 02, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on May 1, 2025, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 45,000 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq

      5/2/25 8:00:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      DALLAS, April 04, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2025, the Compensation Committee of Taysha's Board of Directors granted five new employees, in the aggregate, options to purchase 822,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysh

      4/4/25 8:00:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      DALLAS, March 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) ("Taysha" or the "Company"), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on March 3, 2025, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 225,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with

      3/7/25 8:00:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

      High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4) across both REVEAL trials as of February 2025 data cutoff Completed dosing of the 10 patients in Part A of both REVEAL trials; maturing dataset continues to support advancement toward pivotal Part B trial Productive ongoing discussions with the FDA to solidify regulatory pathway for TSHA-102; update on pivotal trial design expected in H1 2025 Clinical data from cohort two (high dose) and cohort one (low dose) of both REVEAL trials expected in H1 2025 Conference call and live webcast today

      2/26/25 8:00:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26

      DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2024, and host a corporate update conference call and webcast on Wednesday, February 26, 2025, at 8:30 AM Eastern Time. Conference Call DetailsWednesday, February 26, at 8:30 AM Eastern Time / 7:30 AM Central TimeToll Free: 877-407-0792International: 201-689-8263Conference ID: 13751800Webcast: https://ir.tayshagtx.com/news-events/events-p

      2/19/25 8:00:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Taysha Gene Therapies Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Taysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate Update

      DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today reported financial results for the full-year ended December 31, 2020 and provided a corporate update. “In 2020, we successfully completed one of the fastest seed to IPOs in biotech history and made significant strides in advancing our pipeline initiatives, next-generation technology platforms and manufacturing strategy,” said RA Session II, President, Founder and CEO o

      3/3/21 7:00:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Continues to Add Significant Gene Therapy Expertise to Leadership Team with the Appointment of Chief Legal Officer and Chief People Officer

      DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced new additions to its leadership team with the appointments of Timothy J. Douros, J.D., as Chief Legal Officer and Corporate Secretary and Tracy M. Porter, M.Ed., SPHR, as Chief People Officer. Mr. Douros will lead all aspects of the company’s legal organization. Ms. Porter will oversee all aspects of human resources, including operations, talent acquisition and employee development.

      1/26/21 7:00:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Taysha Gene Therapies Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by CHIEF FINANCIAL OFFICER Alam Kamran

      4/A - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

      4/10/25 4:15:13 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF FINANCIAL OFFICER Alam Kamran covered exercise/tax liability with 29,843 shares, decreasing direct ownership by 2% to 1,242,094 units (SEC Form 4)

      4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

      3/13/25 4:15:05 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Nolan Sean P. was granted 892,500 shares, increasing direct ownership by 75% to 2,078,358 units (SEC Form 4)

      4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

      1/3/25 5:38:40 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and Head of R&D Nagendran Sukumar was granted 324,500 shares, increasing direct ownership by 36% to 1,222,343 units (SEC Form 4)

      4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

      1/3/25 5:36:40 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF FINANCIAL OFFICER Alam Kamran was granted 431,000 shares, increasing direct ownership by 51% to 1,271,937 units (SEC Form 4)

      4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

      1/3/25 5:31:21 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Manning Paul B bought $2,999,999 worth of shares (1,333,333 units at $2.25) (SEC Form 4)

      4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

      7/1/24 8:00:07 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Long Alison S was granted 49,220 shares (SEC Form 4)

      4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

      5/31/24 4:18:23 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Stalfort John A Iii was granted 49,220 shares, increasing direct ownership by 5% to 1,098,601 units (SEC Form 4)

      4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

      5/31/24 4:18:25 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Donenberg Phillip B. was granted 49,220 shares, increasing direct ownership by 43% to 163,331 units (SEC Form 4)

      4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

      5/31/24 4:18:21 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sepp-Lorenzino Laura was granted 49,220 shares (SEC Form 4)

      4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

      5/31/24 4:15:09 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Taysha Gene Therapies Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BMO Capital Markets initiated coverage on Taysha Gene Therapies with a new price target

      BMO Capital Markets initiated coverage of Taysha Gene Therapies with a rating of Outperform and set a new price target of $5.00

      6/27/24 7:52:29 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Taysha Gene Therapies with a new price target

      Piper Sandler initiated coverage of Taysha Gene Therapies with a rating of Overweight and set a new price target of $9.00

      4/9/24 8:33:01 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies downgraded by Jefferies with a new price target

      Jefferies downgraded Taysha Gene Therapies from Buy to Hold and set a new price target of $1.50 from $14.00 previously

      2/1/23 6:22:31 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Taysha Gene Therapies from Overweight to Equal-Weight and set a new price target of $3.00 from $23.00 previously

      1/27/23 7:21:49 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies downgraded by Goldman with a new price target

      Goldman downgraded Taysha Gene Therapies from Buy to Neutral and set a new price target of $3.00 from $16.00 previously

      11/9/22 7:24:18 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Taysha Gene Therapies with a new price target

      Robert W. Baird initiated coverage of Taysha Gene Therapies with a rating of Outperform and set a new price target of $26.00

      3/9/22 7:28:47 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Baird initiated coverage on Taysha Gene Therapies with a new price target

      Baird initiated coverage of Taysha Gene Therapies with a rating of Outperform and set a new price target of $26.00

      3/9/22 5:00:02 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wells Fargo initiated coverage on Taysha Gene Therapies with a new price target

      Wells Fargo initiated coverage of Taysha Gene Therapies with a rating of Overweight and set a new price target of $25.00

      3/1/22 7:13:29 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SMBC Nikko initiated coverage on Taysha Gene Therapies with a new price target

      SMBC Nikko initiated coverage of Taysha Gene Therapies with a rating of Outperform and set a new price target of $25.00

      2/18/22 9:21:44 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on Taysha Gene Therapies with a new price target

      Guggenheim initiated coverage of Taysha Gene Therapies with a rating of Buy and set a new price target of $28.00

      12/16/21 8:06:34 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Taysha Gene Therapies Inc. Financials

    Live finance-specific insights

    See more
    • Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Obtained written alignment from the FDA on key elements of TSHA-102 pivotal Part B trial design and next steps on enabling study initiation The FDA advised the Company to submit pivotal Part B trial protocol and associated statistical analysis plan as an amendment to the IND application, eliminating the need for formal end-of-phase meeting and potentially expediting study initiation and registration; IND amendment submission expected in Q2 2025 High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in the pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4) across both REVEAL trials as of April 10, 2025,

      5/15/25 8:00:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

      DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2025, and host a corporate update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM Eastern Time. Conference Call DetailsThursday, May 15, at 8:30 AM Eastern Time / 7:30 AM Central TimeToll Free: 877-407-0792International: 201-689-8263Conference ID: 13753490Webcast: https://ir.tayshagtx.com/news-events/events-presentations

      5/8/25 4:05:00 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

      High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4) across both REVEAL trials as of February 2025 data cutoff Completed dosing of the 10 patients in Part A of both REVEAL trials; maturing dataset continues to support advancement toward pivotal Part B trial Productive ongoing discussions with the FDA to solidify regulatory pathway for TSHA-102; update on pivotal trial design expected in H1 2025 Clinical data from cohort two (high dose) and cohort one (low dose) of both REVEAL trials expected in H1 2025 Conference call and live webcast today

      2/26/25 8:00:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26

      DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2024, and host a corporate update conference call and webcast on Wednesday, February 26, 2025, at 8:30 AM Eastern Time. Conference Call DetailsWednesday, February 26, at 8:30 AM Eastern Time / 7:30 AM Central TimeToll Free: 877-407-0792International: 201-689-8263Conference ID: 13751800Webcast: https://ir.tayshagtx.com/news-events/events-p

      2/19/25 8:00:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one pediatric patient as of data cutoff; IDMC approved continued enrollment in cohort two (high dose) across both REVEAL trials; eight patients dosed to date (low dose=4, high dose=4) Advanced discussions with the FDA on trial design, endpoints and potential use of established natural history dataset for Part B of REVEAL trials, and aligned on a meeting cadence to expedite the development plan for TSHA-102 following initial RMAT Type B meeting FDA approved use of pivotal TSHA-102 product in REVEAL trials based on successful demonstration of analytical comparability; Company released pi

      11/13/24 4:01:00 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      Presented cohort one (low dose) data from both trials of TSHA-102 at 2024 IRSF Rett Syndrome Scientific Meeting that demonstrated durable improvements across consistent clinical domains and an encouraging safety profile in adult (up to 52 weeks) and pediatric (up to 22 weeks) patients TSHA-102 was generally well tolerated with no SAEs or DLTs as of initial six-week assessment in first patient in cohort two (high dose) of adolescent/adult trial; IDMC approved dosing of second (adolescent/adult trial) and first (pediatric trial) patient in cohort two, which is scheduled for Q3 2024   Cohort two (n=3) and cohort one (n=2) data from both trials (adolescent/adult and pediatric) expected in 1H 2

      8/12/24 8:01:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 12

      DALLAS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2024, and host a corporate update conference call and webcast on Monday, August 12, 2024, at 8:30 AM Eastern Time. Conference Call DetailsMonday, August 12, 2024, at 8:30 AM Eastern Time / 7:30 AM Central TimeToll Free:877-407-0792International:201-689-8263Conference ID:13747741Webcast:https://ir.tayshagtx.com/news-events/events-presenta

      8/5/24 8:00:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

      Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen across adult (up to 52 weeks) and pediatric (up to 22 weeks) patients with different genetic mutation severity Longer-term data from both adult patients showed sustained and new improvements across multiple efficacy measures and clinical domains following the completion of steroid taper (patient one: sat unassisted for first time in over a decade, normalized sleep, stabilized seizures; patient two: improved hand stereotypies and breathing, seizure-free for 8.5 months at 25% lowe

      6/18/24 7:30:00 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update

      Completed dosing in cohort one (low dose, 5.7x1014 total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-term data supporting the safety profile and durable response of TSHA-102; enrolled first patient in cohort two (high dose, 1x1015 total vg) with dosing scheduled for Q2 2024 Dosed second pediatric patient in cohort one (low dose, 5.7x1014 total vg) of REVEAL Phase 1/2 pediatric trial in Q1 2024 FDA granted Regenerative Medicine Advanced Therapy designation following review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL trials (adolescent/adult and pediatric) Initial data f

      5/14/24 4:01:00 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14

      DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2024, and host a corporate update conference call and webcast on Tuesday, May 14, 2024, at 4:30 PM Eastern Time. Conference Call DetailsTuesday, May 14, at 4:30 PM Eastern Time / 3:30 PM Central TimeToll Free: 877-407-0792International: 201-689-8263Conference ID: 13745689Webcast: https://ir.tayshagtx.com/news-events/events-pres

      5/7/24 4:05:00 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Taysha Gene Therapies Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Manning Paul B bought $2,999,999 worth of shares (1,333,333 units at $2.25) (SEC Form 4)

      4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

      7/1/24 8:00:07 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Manning Paul B bought $163,000 worth of shares (100,000 units at $1.63) (SEC Form 4)

      4 - Taysha Gene Therapies, Inc. (0001806310) (Issuer)

      11/20/23 7:35:02 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Taysha Gene Therapies Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.

      SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

      11/14/24 5:51:11 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.

      SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

      11/14/24 5:46:12 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Taysha Gene Therapies Inc.

      SC 13G - Taysha Gene Therapies, Inc. (0001806310) (Subject)

      11/14/24 9:40:52 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.

      SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

      11/12/24 10:34:18 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Taysha Gene Therapies Inc. (Amendment)

      SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

      2/14/24 8:44:26 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Taysha Gene Therapies Inc. (Amendment)

      SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

      2/14/24 5:01:36 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Taysha Gene Therapies Inc.

      SC 13G - Taysha Gene Therapies, Inc. (0001806310) (Subject)

      2/14/24 7:08:48 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Taysha Gene Therapies Inc. (Amendment)

      SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

      2/9/24 4:24:55 PM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Taysha Gene Therapies Inc. (Amendment)

      SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

      2/9/24 9:49:31 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Taysha Gene Therapies Inc. (Amendment)

      SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

      9/11/23 8:23:55 AM ET
      $TSHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care